PSMA-targeted SPECT agents: mode of binding effect on in vitro performance. - Wikidata - wikimedia - TriplyDB

PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

http://www.wikidata.org/entity/Q35552454

about

Prostate-specific membrane antigen as a target for cancer imaging and therapy The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer 177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.Multiplex detection of functional G protein-coupled receptors harboring site-specifically modified unnatural amino acids Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA).A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.PET imaging in prostate cancer: focus on prostate-specific membrane antigen ⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer.Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).

P2860

Q26799439-800E03E8-C0C2-47EC-9AB4-D6C88D2B241B Q26849599-88A49DD4-BC23-4FA6-8609-57A5F873209E Q27705945-7D96F399-1530-4A32-9C69-C74A64C2B09C Q33821017-78A9C5D3-00EF-42F2-B2D9-DC21D97DA56C Q35027116-D9F244BB-F165-4FCF-9630-EBDE7C0999ED Q35902274-5A08D5FA-8903-497A-A6EB-E74D5FDBDC87 Q36219010-900FDC86-E3CE-486A-B58E-85462AE23F07 Q36501550-041382B7-4836-40DA-99FA-181A49B34C3F Q37623394-8FE0C1A3-0C17-4392-BC71-605B6CF8B6EC Q38099369-48FEB96C-26F6-4CE1-8B28-97D5DFC98759 Q38705627-2410E1AE-0D30-406A-9A2E-A0CD8A2A5B3A Q38820744-E91A550C-1A46-408E-BC24-0A2EABF7415E Q42620151-43D65DB0-7632-4F6C-B0CE-B9305A363F89

P2860

PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

http://www.wikidata.org/entity/Q35552454

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

@ast

PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

@en

type

label

PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

@ast

PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

@en

prefLabel

PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

@ast

PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

@en

P1433

Q35552454-68937F78-8877-4518-AECC-FAC949DD4AE8

P1476

Q35552454-0085F314-9BF1-40C6-B3E5-36594A13E97F

P2093

Q35552454-0C1E95EC-F552-42E0-80AB-E8BF5D609DF4

Q35552454-1B02516E-76B3-4D02-8FB0-3383EF411ED4

Q35552454-46857888-EE41-4D9C-8BB6-87306B1E545C

Q35552454-9CC09D9D-B503-4DCD-92CF-0941201474A3

Q35552454-D24C3093-56A8-4A95-B228-FA6CB759C48E

Q35552454-F793A06F-582F-4551-9E15-ACA87E3D9100

P2860

Q35552454-0E3F0FE9-A788-4033-AB69-118DA039ED3B

Q35552454-1CEFF2E6-4B18-428E-9ADB-3C1481F55EEF

Q35552454-23E2EE06-7738-4B51-AB59-77495E28D89B

Q35552454-32BC565D-579D-4813-8507-09BC8E32911D

Q35552454-355DA069-8F28-4897-A3EE-31F609C13BCC

Q35552454-36595797-041E-4502-9552-B0BF5198D2BC

Q35552454-386279CB-52F2-446F-B8F1-118C49D88CB8

Q35552454-392971F7-3C35-4CC0-A9E5-55FF9D9F1DEF

Q35552454-3AA03B54-341A-4FE1-B4C0-4E573D580A14

Q35552454-6537AD03-858E-45FA-8F6C-9E1CDC324B4E

P304

Q35552454-39EB8F1A-FF3F-409B-9635-7B3EDE42C7EC

P31

Q35552454-6B6969BA-AC9F-49E8-A7CE-A0ABD6D65975

P356

Q35552454-0D3B79D7-EAC3-44D6-BF09-E72545D22256

P433

Q35552454-FCA9793B-1929-4D06-91A5-49441BB6BB52

P478

Q35552454-F390066F-D777-44AA-BD69-0933F5FC3BAD

P50

Q35552454-EC2DF8E4-8730-48D9-AD90-CFDEBB9A6F07

P577

Q35552454-E60E7DA6-16D7-4C11-935E-6E82EA3CA151

P5875

Q35552454-38C2A084-CD94-4447-992F-5B123890C239

P698

Q35552454-41D63F0C-A662-4622-8C34-42CA40F20B0D

P932

Q35552454-276F7B55-0FC5-4F42-BD8D-0D39D976FDC0

P356

P1433

P1476

PSMA-targeted SPECT agents: mode of binding effect on in vitro performance

@en

P2093

Adam L Moore

http://www.w3.org/2001/XMLSchema#string

Clifford E Berkman

http://www.w3.org/2001/XMLSchema#string

Jessie R Nedrow-Byers

http://www.w3.org/2001/XMLSchema#string

Mark R Hopkins

http://www.w3.org/2001/XMLSchema#string

Paul D Benny

http://www.w3.org/2001/XMLSchema#string

Tanushree Ganguly

http://www.w3.org/2001/XMLSchema#string

P2860

Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer

High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors

Prostate-specific membrane antigen expression as a predictor of prostate cancer progression

Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase

In vivo cancer targeting and imaging with semiconductor quantum dots

The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen.

Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging.

Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway.

Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.

P304

355-362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.22575

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

Melody D Fulton

P577

2012-08-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230714701

http://www.w3.org/2001/XMLSchema#string

P698

22911263

http://www.w3.org/2001/XMLSchema#string

P932

4414331

http://www.w3.org/2001/XMLSchema#string